Serial No: 09/423,715 Filed: January 12, 2000

Page: 2

Please amend the subject application as follows:

In the Specification

Please add new page -25- containing the Abstract of the Invention, attached hereto as **Exhibit A**.

In the Claims

1.

Please amend the claims in accordance with 37 C.F.R. §1.121 as follows. The marked-up version of the claims reflecting the changes appears in Attachment A hereto.

pharmacologically desirable, topical (Amended) acceptable composition for mutual pharmaceutical \(\)y transdermal permeation of at least a first enhancement of and a second pharmaceutically acceptable components which are both pharmacol δ gically active agents, the composition comprising an emulsion of at least one discontinuous phase in a continuous phase, the or each discontinuous phase first and eutectid mixture of comprising а pharmacologically active\ agents that are desirable for transdermal permeation and the continuous phase comprising a pharmaceutically acceptable carrier, the eutectic mixture having a melting point below 40°C; and at least one compatible emulsifying agent, with the provisos that when first pharmacologically adtive agent is anesthetic, the second pharmacologically active agent is when the second anaesthetic or, local а not pharmacologicaly active agent is a local anesthetic, the first pharmacologically active agent is not a local anesthetic.

put Dont 6.

(Amended) The topical composition according to Claim 3, in which the topical composition additionally includes, in the

Serial No: 09/423,715 Filed: January 12, 2000

Page: 3

eutectic mixture,

fourth pharmaceutically acceptable

component.

p3

11. (Amended) The topical composition according to Claim 1, in which the second pharmacologically active agent is selected from the group consisting of non-steroid anti-inflammatory arylpropionic agents, narcotic analgesics, anti-fungal agents, antibacterial agents, anticholinergics, anthelmintics, antihistaminics, and antihypertensives.

Port D,

- 12. (Amended) The topical composition according to Claim 8, in which the third and fourth pharmacologically active agents are each selected from the group consisting of non-steroid anti-inflammatory agents, narcotic analgesics, anti-fungal agents, antibacterial agents, anticholinergics, antihypertensives, antihistaminics, and anthelmintics.
- 13. (Amended) The topical composition according to Claim 3 or 4, in which the third pharmaceutically acceptable component is lauric acid, stearyl alcohol, menthol, thymol, cinnamic acid or an ester thereof.

pmpo,

(Amended) The topical composition according to Claim 15, in 16. which the gelling or suspension agent is selected from the modified , celluloses, consisting of carbomers, semi-synthetic synthetic or gums, naturally-occurring co-polymers formed between maleic \(\) modified . starches, anhydride and methyl vinyl ether, colloidal silica and methacrylates or a mixture thereof

 θ_{Q}

for mutual enhancement of dermal method 23. (Amended) least а first and second of at permeation acceptable components which are both pharmaceutically

Serial No: 09/423,715 Filed: January 12, 2000

Page: 4

PS -

pharmacologicall χ active agents, the method comprising applying a topical composition for mutual enhancement of transdermal permeation of at least first and second active the composition agents, pharmacologically comprising an emulsion of at least one discontinuous phase in a continuous phase igwedge the or each discontinuous phase comprising a eutectic mixture of first and second pharmacologically active agents and the continuous phase comprising a pharmaceutically acceptable carrier, eutectic mixture having a \backslash melting point below 40°C; and least one compatible Amulsifying agent, with the provisos that , when the first pharmacologically active agent is a local anesthetic, the second pharmacologically agent is not a local anesthetic, or, when the second pharmacologically active agent is a local anesthetic, the first pharmacologically acitve agent is not a local anesthetic, to an accessible body surface of an animal.

buto's

- 29. (Amended) The topical composition according to Claim 12, wherein the third and fourth pharmacologically active agents are each selected from the group consisting of triclosan, chlorocresol, capsaicin, trimeprazine, choline salicylate, methyl nicotinate, ibuprofen, ketoprofen, fenoprofen, flurbiprofen, etodolac, fentanyl, econazole, ketoconazole, mupirocin, chloroutanol, clindamycin, iodine, oxybutynin, propranolol, triprolidine, promethazine, and tetramisole.
- 30. (Amended) The topical composition according to Claim 16, wherein the gelling or suspension agent is selected from the group consisting of xanthan gum, acacia, tragacanth, and a mixture thereof.


Serial No: 09/423,715 Filed: January 12, 2000

Page: 5

Please also add new claims 31-37 as follows:



- 31. (New) The topical composition according to Claim 9, in which said at least one discontinuous phase contains no cosolvent or additional oil phase, so that the eutectic mixture essentially comprises the or each discontinuous phase of the emulsion.
- 32. (New) The topical composition according to Claim 14, in which the pharmaceutically acceptable carrier is substantially hydrophilic, said carrier containing essentially water as the continuous phase.





- 34. (New) The method according to Claim 23, in which said at least one discontinuous phase contains no co-solvent or additional oil phase, so that the eutectic mixture substantially comprises the or each discontinuous phase of the emulsion.
- 35. (New) The method according to Claim 33, in which said at least one discontinuous phase contains no co-solvent or additional oil phase, so that the eutectic mixture essentially comprises the or each discontinuous phase of the emulsion.
- 36. (New) The method according to Claim 23, in which the pharmaceutically acceptable carrier is substantially hydrophilic, said carrier containing substantially water as the continuous phase.

Serial No: 09/423,715 Filed: January 12, 2000

Page: 6

37. (New) The method according to Claim 25, in which the pharmaceutically acceptable carrier is substantially hydrophilic, said carrier containing essentially water as

the continuous phase.